BioSpace News Archive

iSchemaView, the worldwide leader in advanced imaging for stroke, has received registration approval under the Japanese Pharmaceutical Affairs Law through third party review by the Japanese Association for the Advancement of Medical Equipment for its RAPID imaging platform.

Vivacelle Bio, Inc. announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer, an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and efficacy of VBI-S.

CEL-SCI Corporation (NYSE American: CVM) announced that one of its key collaborators from Rush University Medical center, Dr. Adrienn Markovitz an Assistant professor in the department of Orthopedic Surgery, presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry in San Francisco, California on Wednesday July 3, 2019.

OncoSenX, Inc., a late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, today announced it has raised $3 million in pre-seed funding to advance its pipeline.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, commercially launched DEXYCU® (dexamethasone intraocular suspension) 9% in March 2019 in the United States. DEXYCU is the first and only U.S. Food and Drug Administration (FDA) approved intraocular steroid

Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that it has retained Lighthouse BioPartners, LLC

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today new clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy targeting cancer stem cells

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2019 financial and operating results on Tuesday, August 6, 2019, before the U.S. financial markets open.

Kalderos Director of Industry Relations Steve Zielinski will address the significance of duplicate discounts and how Kalderos’ data-rich and insights-driven platform ensures compliance.

According to Coherent Market Insights, the global natural language processing in healthcare and life sciences market was valued at US$ 1,497.89 million in 2018, and is projected to exhibit a CAGR of 26.8% during the forecast period.